These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35262371)

  • 1. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
    Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
    J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type III and Not Type I Interferons Efficiently Prevent the Spread of Rotavirus in Human Intestinal Epithelial Cells.
    Doldan P; Dai J; Metz-Zumaran C; Patton JT; Stanifer ML; Boulant S
    J Virol; 2022 Sep; 96(17):e0070622. PubMed ID: 36000839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of SARS-CoV-2 by type I and type III interferons.
    Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
    J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING.
    Karlowitz R; Stanifer ML; Roedig J; Andrieux G; Bojkova D; Bechtel M; Smith S; Kowald L; Schubert R; Boerries M; Cinatl J; Boulant S; van Wijk SJL
    Cell Death Dis; 2022 Aug; 13(8):684. PubMed ID: 35933402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.
    Jafarzadeh A; Nemati M; Saha B; Bansode YD; Jafarzadeh S
    Viral Immunol; 2021 Jun; 34(5):307-320. PubMed ID: 33147113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
    Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
    Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudorabies virus-induced expression and antiviral activity of type I or type III interferon depend on the type of infected epithelial cell.
    Yin Y; Ma J; Van Waesberghe C; Devriendt B; Favoreel HW
    Front Immunol; 2022; 13():1016982. PubMed ID: 36405751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
    Park A; Iwasaki A
    Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection.
    Sohn SY; Hearing J; Mugavero J; Kirillov V; Gorbunova E; Helminiak L; Mishra S; Mackow E; Hearing P; Reich NC; Kim HK
    mBio; 2021 Dec; 12(6):e0275621. PubMed ID: 34724828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2.
    Hatton CF; Botting RA; Dueñas ME; Haq IJ; Verdon B; Thompson BJ; Spegarova JS; Gothe F; Stephenson E; Gardner AI; Murphy S; Scott J; Garnett JP; Carrie S; Powell J; Khan CMA; Huang L; Hussain R; Coxhead J; Davey T; Simpson AJ; Haniffa M; Hambleton S; Brodlie M; Ward C; Trost M; Reynolds G; Duncan CJA
    Nat Commun; 2021 Dec; 12(1):7092. PubMed ID: 34876592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I and III interferons are good markers to monitor COVID-19 pathophysiology.
    Darif D; Ejghal R; Desterke C; Outlioua A; Hammi I; Lemrani M; Hilali F; Guessous F; Zaid Y; Akarid K
    Cytokine; 2023 May; 165():156172. PubMed ID: 36924609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
    Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.
    Stanifer ML; Kee C; Cortese M; Zumaran CM; Triana S; Mukenhirn M; Kraeusslich HG; Alexandrov T; Bartenschlager R; Boulant S
    Cell Rep; 2020 Jul; 32(1):107863. PubMed ID: 32610043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces.
    Stanifer ML; Guo C; Doldan P; Boulant S
    Front Immunol; 2020; 11():608645. PubMed ID: 33362795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection.
    Chiale C; Greene TT; Zuniga EI
    Immunol Rev; 2022 Aug; 309(1):12-24. PubMed ID: 35775361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The problem of the use of interferons in the novel coronavirus disease COVID-19 (Coronaviridae: Coronavirinae: Betacoronavirus: Sarbecovirus)].
    Ershov FI; Narovlyansky AN
    Vopr Virusol; 2022 May; 67(2):115-125. PubMed ID: 35521984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpesviruses and the Type III Interferon System.
    Yin Y; Favoreel HW
    Virol Sin; 2021 Aug; 36(4):577-587. PubMed ID: 33400088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-
    Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH
    Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.